Patient Portal

Daniel Morgensztern, MD

Associate Professor, Medicine
Division of Oncology
Section of Medical Oncology

Specialty Areas

Oncology
Lung Cancer
Medical Oncology
Thoracic Oncology
Esophageal Cancer

Board Certifications

Oncology
Internal Medicine

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Medical oncology, lung cancer

  • Maps & Directions
  • Education
  • Publication & Research

Maps & Directions

Maps & Directions

Siteman Cancer Center - South County

5225 MidAmerica Plaza
St. Louis, MO 63129

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: (314) 747-7222
Additional Phone: (800) 600-3606

Education

Education

Medical Degree: Fundacao Tecnico-Educacional Souza Marques, Brazil 1995
Residency, Internal Medicine: University of Miami Hospital, Miami, FL 2001
Fellowship, Hematology-Oncology: University of Miami, Miami, FL 2004
Residency, Internal Medicine and Hematology: State University of Rio de Janeiro, Brazil 1998

Publication & Research

Publication & Research

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
Drilon A, Fu S, Patel MR, Fakih M, Wang D, Olszanski AJ, Morgensztern D, Liu SV, Cho BC, Bazhenova L, Rodriguez CP, Doebele RC, Wozniak A, Reckamp KL, Seery T, Nikolinakos P, Hu Z, Oliver J, Trone D, McArthur K, Patel R, Multani PS, Ahn MJ
Cancer Discov. 2018 Nov 28; pii: CD-18-0839. doi: 10.1158/2159-8290.CD-18-0839.

PMID:
    30487236
    [PubMed - as supplied by publisher]
Related citations


Lorlatinib: a new-generation drug for ALK-positive NSCLC.
Waqar SN, Morgensztern D
Lancet Oncol. 2018 Dec; 19(12)1555-1557. doi: 10.1016/S1470-2045(18)30789-7.

PMID:
    30413381
    [PubMed - in process]
Related citations


ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, The Abound L Investigators
Cancer. 2018 Nov 1; doi: 10.1002/cncr.31779.

PMID:
    30383906
    [PubMed - as supplied by publisher]
Related citations


NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.
Kalemkerian GP, Loo BW Jr, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Santana-Davila R, Williams CC Jr, Hoffmann KG, Hughes M
J Natl Compr Canc Netw. 2018 Oct; 16(10)1171-1182. doi: 10.6004/jnccn.2018.0079.

PMID:
    30323087
    [PubMed - in process]
Related citations


First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH, Weekes CD, Nemunaitis J, Ramanathan RK, Heist RS, Morgensztern D, Angevin E, Bauer TM, Yue H, Motwani M, Parikh A, Reilly EB, Afar D, Naumovski L, Kelly K
J Clin Oncol. 2018 Oct 4; JCO2018787697. doi: 10.1200/JCO.2018.78.7697.

PMID:
    30285518
    [PubMed - as supplied by publisher]
Related citations


Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer.
Wagner AH, Devarakonda S, Skidmore ZL, Krysiak K, Ramu A, Trani L, Kunisaki J, Masood A, Waqar SN, Spies NC, Morgensztern D, Waligorski J, Ponce J, Fulton RS, Maggi LB Jr, Weber JD, Watson MA, O'Conor CJ, Ritter JH, Olsen RR, Cheng H, Mukhopadhyay A, Can I, Cessna MH, Oliver TG, Mardis ER, Wilson RK, Griffith M, Griffith OL, Govindan R
Nat Commun. 2018 Sep 17; 9(1)3787. doi: 10.1038/s41467-018-06162-9.

PMID:
    30224629
    [PubMed - in process]
Related citations


Non-small-cell Lung Cancer With Brain Metastasis at Presentation.
Waqar SN, Samson PP, Robinson CG, Bradley J, Devarakonda S, Du L, Govindan R, Gao F, Puri V, Morgensztern D
Clin Lung Cancer. 2018 Jul; 19(4)e373-e379. doi: 10.1016/j.cllc.2018.01.007.

PMID:
    29526531
    [PubMed - in process]
Related citations


Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer.
Morgensztern D, Samson PS, Waqar SN, Devarakonda S, Robinson CG, Govindan R, Puri V
J Thorac Oncol. 2018 Apr; 13(4)543-549. doi: 10.1016/j.jtho.2018.01.010.

PMID:
    29410127
    [PubMed - in process]
Related citations


The biology and management of non-small cell lung cancer.
Herbst RS, Morgensztern D, Boshoff C
Nature. 2018 Jan 24; 553(7689)446-454. doi: 10.1038/nature25183.

PMID:
    29364287
    [PubMed - indexed for MEDLINE]
Related citations


Percutaneous Image-Guided Ablation in the Treatment of Osseous Metastases from Non-small Cell Lung Cancer.
Ma Y, Wallace AN, Waqar SN, Morgensztern D, Madaelil TP, Tomasian A, Jennings JW
Cardiovasc Intervent Radiol. 2018 May; 41(5)726-733. doi: 10.1007/s00270-017-1843-6.

PMID:
    29204695
    [PubMed - indexed for MEDLINE]
Related citations


<i>nab</i>-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy.
Thomas M, Spigel DR, Jotte RM, McCleod M, Socinski MA, Page RD, Gressot L, Knoble J, Juan O, Morgensztern D, Isla D, Kim ES, West H, Ko A, Ong TJ, Trunova N, Gridelli C
Lung Cancer (Auckl). 2017; 8207-216. doi: 10.2147/LCTT.S138570.

PMID:
    29138610
    [PubMed]
Related citations


Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas.
Oronsky B, Ma PC, Morgensztern D, Carter CA
Neoplasia. 2017 Dec; 19(12)991-1002. doi: 10.1016/j.neo.2017.09.002.

PMID:
    29091800
    [PubMed - indexed for MEDLINE]
Related citations


Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M, PACIFIC Investigators.
N Engl J Med. 2017 Nov 16; 377(20)1919-1929. doi: 10.1056/NEJMoa1709937.

PMID:
    28885881
    [PubMed - indexed for MEDLINE]
Related citations


Treatment advances in small cell lung cancer (SCLC).
Waqar SN, Morgensztern D
Pharmacol Ther. 2017 Dec; 18016-23. doi: 10.1016/j.pharmthera.2017.06.002.

PMID:
    28579387
    [PubMed - indexed for MEDLINE]
Related citations


Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer.
Ahmad U, Crabtree TD, Patel AP, Morgensztern D, Robinson CG, Krupnick AS, Kreisel D, Jones DR, Patterson GA, Meyers BF, Puri V
Ann Thorac Surg. 2017 Jul; 104(1)303-307. doi: 10.1016/j.athoracsur.2017.01.069.

PMID:
    28433225
    [PubMed - indexed for MEDLINE]
Related citations


Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer.
Samson P, Crabtree TD, Robinson CG, Morgensztern D, Broderick S, Krupnick AS, Kreisel D, Patterson GA, Meyers B, Puri V
Ann Thorac Surg. 2017 Apr; 103(4)1070-1075. doi: 10.1016/j.athoracsur.2016.09.053.

PMID:
    28110809
    [PubMed - indexed for MEDLINE]
Related citations


Precision medicine in lung cancer: the battle continues.
Waqar SN, Morgensztern D
J Thorac Dis. 2016 Nov; 8(11)2991-2993. doi: 10.21037/jtd.2016.11.46.

PMID:
    28066565
    [PubMed]
Related citations


MINI01.20: Interim Quality of Life (QoL) Results from ABOUND.sqm: nab-Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Topic: Medical Oncology.
Thomas M, Page R, Gressot L, Daniel D, Morgensztern D, Levy B, Hussein M, Razaq M, Villaflor VM, Aix SP, Sivarajan K, Engel-Riedel W, Staib P, Ko A, Ong TJ, Trunova N, Spigel DR
J Thorac Oncol. 2016 Nov; 11(11S)S269. doi: 10.1016/j.jtho.2016.09.035.

PMID:
    27969468
    [PubMed]
Related citations


ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology.
Bauer TM, Spigel D, Ready N, Morgensztern D, Glisson BS, Byers LA, Burris H, Robert F, Strickland DK, Pietanza MC, Govindan R, Dylla SJ, Peng S, Rudin C
J Thorac Oncol. 2016 Nov; 11(11S)S252-S253. doi: 10.1016/j.jtho.2016.09.010.

PMID:
    27969444
    [PubMed]
Related citations


Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.
Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR, SCRX16-001 investigators.
Lancet Oncol. 2017 Jan; 18(1)42-51. doi: 10.1016/S1470-2045(16)30565-4.

PMID:
    27932068
    [PubMed - indexed for MEDLINE]
Related citations